top of page
Якорь 5
 Lyme Disease Global Pandemia

Lyme Disease spreads like a Pandemic, often eluding proper management in clinics, leading to far-reaching health consequences. At Deep Knowledge Group and Longevity Industry Analytics, we understand this crisis and possess the deep knowledge needed to curb this pandemic's effects. Our aim is clear: to halt this widespread disease and prevent its lasting health implications.

Our expertise in this field, coupled with our advanced clinics, positions us uniquely to combat Lyme Disease. We're actively seeking investors and partners to join us in revolutionizing the approach to tackling this pressing global issue. Together, let's make a significant impact on Lyme Disease management and pave the way for a healthier future.

Percent of people who had Lyme Disease

Global Perspective

Lyme Disease is one of the most frequently diagnosed tick-borne infections worldwide. A recent study* suggests that more than one hundred million people are currently infected or have previously had this illness. Understanding factors influencing Lyme prevalence is crucial for effective prevention, diagnosis, and management.

Many individuals worldwide grapple with consequences of Lyme disease, experiencing conditions such as persistent inflammation and compromised immune function. Moreover, Lyme disease has been implicated in provoking or accelerating the development of age-related diseases. The aftermath of Lyme disease can manifest in various ways, impacting the well-being of those affected and highlighting the intricate relationship between Lyme disease and the onset or progression of conditions associated with aging.

* Dong, Y., (2022). Global seroprevalence and sociodemographic characteristics of Borrelia burgdorferi sensu lato in human populations: a systematic review and meta-analysis. In BMJ Global Health (Vol. 7, Issue 6). BMJ.

The global perspective on Lyme Disease extends beyond research, involving collaborative  efforts to raise awareness and foster understanding. Analytical groups, healthcare and government organizations, and affected communities worldwide are joining forces to shed light on the challenges posed by Lyme disease. This collective approach aims to promote education about prevention, early detection, and effective management. By fostering a global

dialogue, DKG strives to create a unified front against Lyme disease Pandemia, emphasizing the need for continued research, improved diagnostics, and accessible advansed treatment options on an international scale. The shared commitment to addressing this global health concern underscores the importance of solidarity in the face of a widespread and complex Global Health Challenge.

Lyme Disease Ecosystem

Lyme Disease Global Pandemia GeoDashboard


Clinic Trials 






Data Points 

Якорь 3

Lyme Disease
Global Pandemia Dashboard

Lyme Disease Global  Pandemia Dashboard is a centralized hub designed to meet all the market and business intelligence needs of its users. It offers comprehensive support, encompassing benchmarking for companies, technologies, and thorough competitive and SWOT analysis for over 105 clinical trials, 1000+ companies, 140 investors, and a staggering 17,000 data inputs within the Lyme disease sector.

Снимок экрана 2023-12-09 в 14.27.38.png
Снимок экрана 2023-12-15 в 12.52.40.png

Lyme Market in Charts

Anticipated to show remarkable progress, the Global Lyme disease treatment market is poised to surge from USD 805.00 Million in 2022 to USD 1,820.09 Million in 2032, marking an impressive Compound Annual Growth Rate of around 8.5%. The surge in the market owes its momentum to several key factors. Among these are the increasing number of reported Lyme disease cases, substantial investments by major healthcare entities, advancements in the healthcare infrastructure, and the introduction of highly precise diagnostic methods like Spectroscopic testing, with a notable focus on Raman spectroscopy testing. Together, these elements synergize to not only drive but sustain the consistent expansion of the market, indicative of a growing and persistent demand for more effective treatments and diagnostic solutions for Lyme disease.

Lyme Disease Diagnostics Market Size, $bn

During this period, the Compound Annual Growth Rate stands at 6.5%. This growth can be attributed to several factors, including heightened awareness and reporting of Lyme disease cases, advancements in diagnostic technologies, and ongoing investments in research and development to create more precise and effective tools for detecting Lyme disease.

Projections indicate a consistent market expansion from
USD 2.52 Billion in 2022 to USD 4 Billion in 2032. This emphasizes the rising need for sophisticated diagnostic tools in detecting Lyme disease, promising earlier diagnosis and enhanced condition management.

Solutions for Lyme Pandemia 

The Lyme Pandemic poses a significant challenge, with a growing pharmaceutical market each year. Despite this expansion, the issue persists, highlighting the complexity and difficulty in finding a comprehensive resolution to the problem. Lyme Disease are not effectively addressed solely through standard antibiotic treatments.


At DKG, we frequently encounter people facing challenges in managing their symptoms even after undergoing conventional antibiotic therapy. Drawing on over a decade of analytical expertise, we have accumulated and explored advanced holistic methods to effectively impact on the spread of Lyme Disease Pandemia in the World. Comprehensive addressing of these symptoms is vital, as untreated cases may lead to potential physical or psychological impairment.

Our proficiency in treating Lyme disease revolves around discerning the coinfections and other complicating factors associated with this  ailment. To tackle this distinct set of considerations for each patient, our specialists employ personalized proprietary treatments that integrate cutting-edge and natural therapies related to Mitochondrial, Space, Restorative, Functional Medicine within the framework of Longevity Medicine.

Снимок экрана 2024-02-08 в 20.58.07.png
Снимок экрана 2024-02-08 в 20.59.02.png
Снимок экрана 2024-02-08 в 21.00.31.png
Снимок экрана 2024-02-08 в 21.01.44.png

Lyme Patient Logistic Pathway

Explore the comprehensive journey of Lyme patients through the interactive logistic pathway. Each stage provides a brief overview, and by clicking on individual stages, you can access detailed descriptions, offering insights into AI-based diagnostic, treatment, and management processes specific to Lyme disease. For more in-depth information about clinics, diagnostics, and treatments, use the Lyme Disease Global Pandemic Dashboard.

Якорь 4


Lyme Teaser new.png

One Pager

Lyme one-pager new.png


Lyme Report new.png

Read More

Lyme Disease Clinical Trials

The United States stands as the primary research center for Lyme Disease studies, hosting over 46% of these clinical trials.


Slovenia spearheads the European contribution with over 17% of clinical trials, followed by approximately 9% in France. Combined, European nations contribute to more than 47% of these trials.

After 2019, the annual number of clinical trials more than doubled increasing to 8.4 studies per year. The jump in clinical trials after 2019 signals a rising awareness of Lyme Disease significance.

The most significant players in the market are University Medical Centre Ljubljana (Slovenia), National Institute of Allergy and Infectious Diseases (NIAID) (USA), Pfizer (USA), University Hospital, Strasbourg (France), Sorlandet Hospital HF (Norway), and Research Foundation for Mental Hygiene, Inc. (USA).

Lyme Disease may Trigger Cancer

Untreated Lyme infections can have serious consequences, such as extended hospitalization, chronic symptoms, and in some instances, the onset of autoimmune disorders and cancers. Clinical research* suggests that the bacteria B. burgdorferi, associated with Lyme, may contribute to the development of cancers. Obtaining an accurate diagnosis and comprehensive treatment is essential to avoid these severe outcomes.

*Smith, A. , Oertle, J. and Prato, D. (2014) Cancer and Infectious Causes. Open Journal of Medical Microbiology, 4, 161-177. doi: 10.4236/ojmm.2014.43019.

Strategic Partner Projects


Alzheimer's Global

Challenge Ecosystem


Autism Global

Challenge Ecosystem